Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a promising company with a strong human diagnostics and monitoring focus, backed by revolutionary science and a dedicated team. However, recent reverse split actions may have negatively impacted stock value, shareholder base and liquidity, requiring time to repair and potentially indicating further shareholder concerns for the future. As an analyst it would be important to closely monitor future financial reports and announcements to fully assess the impact of the reverse split on the company's long-term growth potential.

Bears say

VolitionRX is facing several risks to achieving success, including potential barriers to regulatory or clinical approval, financial hurdles and potential market share losses. Although the company's recent study showed promise in detecting cancer, a concerning level of debt and the need for future capital raises could add significant pressure to the stock. Furthermore, competition in the liquid biopsy market and the company's struggle to establish commercial traction could impede its growth potential.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.